Succinic Acid

Succinic Acid

SCHEMBL507213

Clc1ccc2c(c1NCc1ccc(-c3csnn3)cc1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR2A known ✓ P28223 1/20 0.33
HTR2C known ✓ P28335 1/20 0.33
DPP4 known ✓ P27487 1/20 0.33
MGLL Q99685 1/20 0.39
PTPN1 P18031 7/20 0.36
MDM2 Q00987 1/20 0.34
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
AGTR1 P30556 1/20 0.33
HTR2B P41595 1/20 0.33
ADAM17 P78536 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
IDH1 O75874 1/20 0.33
KMT2A Q03164 1/20 0.33
AKT1 P31749 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL506999 0.85 MEN1 (0.37) MAPTHTR2AHTR2CHTR2BKMT2A
Succinic Acid SCHEMBL507439 0.84 DVL1 (0.40) GAAMAPTKMT2A
Succinic Acid SCHEMBL10476196 0.84 FFAR1 (0.44) HTR2AHTR2CHTR2BKMT2A
Succinic Acid SCHEMBL507099 0.83 HCAR2 (0.39) HTR2AHTR2CHTR2B
Succinic Acid SCHEMBL2582412 0.83 ALDH1A1 (0.48) GAAMAPTKMT2A
Succinic Acid SCHEMBL2580275 0.83 RAB9A (0.40) GAAMAPTKMT2A
Succinic Acid SCHEMBL506304 0.83 FFAR1 (0.44) GAAHTR2AHTR2CHTR2BKMT2A
Succinic Acid SCHEMBL13685292 0.82 MAPT (0.44) GAAMAPTKMT2A
Succinic Acid SCHEMBL13685413 0.81 MAPT (0.40) GAAMAPTHTR2BKMT2A
Succinic Acid SCHEMBL13685314 0.81 ALDH1A1 (0.40) GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 HTR2A 4/4885HTR2C 1/4885DPP4 1322/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HTR2A 4/4885HTR2C 1/4885DPP4 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.